Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1988 Nov;65(3):329–335.

Therapeutic strategies with monoclonal antibodies and immunoconjugates.

V S Byers 1, R W Baldwin 1
PMCID: PMC1385468  PMID: 3061932

Full text

PDF
329

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med. 1985 Aug 8;313(6):337–342. doi: 10.1056/NEJM198508083130601. [DOI] [PubMed] [Google Scholar]
  2. Baldwin R. W., Byers V. S. Monoclonal antibodies and immunoconjugates for cancer treatment. Cancer Chemother Biol Response Modif. 1987;9:409–431. [PubMed] [Google Scholar]
  3. Benjamin R. J., Cobbold S. P., Clark M. R., Waldmann H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med. 1986 Jun 1;163(6):1539–1552. doi: 10.1084/jem.163.6.1539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blakey D. C., Skilleter D. N., Price R. J., Thorpe P. E. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. Biochim Biophys Acta. 1988 Feb 22;968(2):172–178. doi: 10.1016/0167-4889(88)90005-5. [DOI] [PubMed] [Google Scholar]
  5. Bourrie B. J., Casellas P., Blythman H. E., Jansen F. K. Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur J Biochem. 1986 Feb 17;155(1):1–10. doi: 10.1111/j.1432-1033.1986.tb09451.x. [DOI] [PubMed] [Google Scholar]
  6. Byers V. S., Pawluczyk I., Pawlucyzk I., Berry N., Durrant L., Robins R. A., Garnett M. C., Price M. R., Baldwin R. W. Potentiation of anti-carcinoembryonic antigen immunotoxin cytotoxicity by monoclonal antibodies reacting with co-expressed carcinoembryonic antigen epitopes. J Immunol. 1988 Jun 1;140(11):4050–4055. [PubMed] [Google Scholar]
  7. Byers V. S., Pimm M. V., Pawluczyk I. Z., Lee H. M., Scannon P. J., Baldwin R. W. Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents. Cancer Res. 1987 Oct 15;47(20):5277–5283. [PubMed] [Google Scholar]
  8. Campbell A. M., Whitford P., Leake R. E. Human monoclonal antibodies and monoclonal antibody multispecificity. Br J Cancer. 1987 Dec;56(6):709–713. doi: 10.1038/bjc.1987.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cheung N. K., Lazarus H., Miraldi F. D., Abramowsky C. R., Kallick S., Saarinen U. M., Spitzer T., Strandjord S. E., Coccia P. F., Berger N. A. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987 Sep;5(9):1430–1440. doi: 10.1200/JCO.1987.5.9.1430. [DOI] [PubMed] [Google Scholar]
  10. Corvalan J. R., Smith W. Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer Immunol Immunother. 1987;24(2):127–132. doi: 10.1007/BF00205589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Corvalan J. R., Smith W., Gore V. A., Brandon D. R., Ryde P. J. Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody. Cancer Immunol Immunother. 1987;24(2):138–143. doi: 10.1007/BF00205591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dietrich A. J., Nelson E. C., Kirk J. W., Zubkoff M., O'Connor G. T. Do primary physicians actually manage their patients' fee-for-service care? JAMA. 1988 Jun 3;259(21):3145–3149. [PubMed] [Google Scholar]
  13. Dillman R. O., Beauregard J. C., Sobol R. E., Royston I., Bartholomew R. M., Hagan P. S., Halpern S. E. Lack of radioimmunodetection and complications associated with monoclonal anticarcinoembryonic antigen antibody cross-reactivity with an antigen on circulating cells. Cancer Res. 1984 May;44(5):2213–2218. [PubMed] [Google Scholar]
  14. Endo N., Takeda Y., Umemoto N., Kishida K., Watanabe K., Saito M., Kato Y., Hara T. Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates. Cancer Res. 1988 Jun 15;48(12):3330–3335. [PubMed] [Google Scholar]
  15. Endo Y., Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem. 1987 Jun 15;262(17):8128–8130. [PubMed] [Google Scholar]
  16. Fahey J. L., Sarna G., Gale R. P., Seeger R. Immune interventions in disease. Ann Intern Med. 1987 Feb;106(2):257–274. doi: 10.7326/0003-4819-106-2-257. [DOI] [PubMed] [Google Scholar]
  17. FitzGerald D. J., Bjorn M. J., Ferris R. J., Winkelhake J. L., Frankel A. E., Hamilton T. C., Ozols R. F., Willingham M. C., Pastan I. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. Cancer Res. 1987 Mar 1;47(5):1407–1410. [PubMed] [Google Scholar]
  18. Fulton R. J., Blakey D. C., Knowles P. P., Uhr J. W., Thorpe P. E., Vitetta E. S. Purification of ricin A1, A2, and B chains and characterization of their toxicity. J Biol Chem. 1986 Apr 25;261(12):5314–5319. [PubMed] [Google Scholar]
  19. Garnett M. C., Baldwin R. W. An improved synthesis of a methotrexate-albumin-791T/36 monoclonal antibody conjugate cytotoxic to human osteogenic sarcoma cell lines. Cancer Res. 1986 May;46(5):2407–2412. [PubMed] [Google Scholar]
  20. Griffin T. W., Richardson C., Houston L. L., LePage D., Bogden A., Raso V. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Cancer Res. 1987 Aug 15;47(16):4266–4270. [PubMed] [Google Scholar]
  21. Herlyn D., Ross A. H., Iliopoulos D., Koprowski H. Induction of specific immunity to human colon carcinoma by anti-idiotypic antibodies to monoclonal antibody CO17-1A. Eur J Immunol. 1987 Nov;17(11):1649–1652. doi: 10.1002/eji.1830171120. [DOI] [PubMed] [Google Scholar]
  22. Herlyn D., Wettendorff M., Schmoll E., Iliopoulos D., Schedel I., Dreikhausen U., Raab R., Ross A. H., Jaksche H., Scriba M. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci U S A. 1987 Nov;84(22):8055–8059. doi: 10.1073/pnas.84.22.8055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Humm J. L. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986 Sep;27(9):1490–1497. [PubMed] [Google Scholar]
  24. Jaffers G. J., Fuller T. C., Cosimi A. B., Russell P. S., Winn H. J., Colvin R. B. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation. 1986 May;41(5):572–578. doi: 10.1097/00007890-198605000-00004. [DOI] [PubMed] [Google Scholar]
  25. James K., Bell G. T. Human monoclonal antibody production. Current status and future prospects. J Immunol Methods. 1987 Jun 26;100(1-2):5–40. doi: 10.1016/0022-1759(87)90170-0. [DOI] [PubMed] [Google Scholar]
  26. Khazaeli M. B., Saleh M. N., Wheeler R. H., Huster W. J., Holden H., Carrano R., LoBuglio A. F. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst. 1988 Aug 17;80(12):937–942. doi: 10.1093/jnci/80.12.937. [DOI] [PubMed] [Google Scholar]
  27. Lowder J. N., Meeker T. C., Campbell M., Garcia C. F., Gralow J., Miller R. A., Warnke R., Levy R. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood. 1987 Jan;69(1):199–210. [PubMed] [Google Scholar]
  28. May R. D., Vitetta E. S., Moldenhauer G., Dörken B. Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. Cancer Drug Deliv. 1986 Fall;3(4):261–272. doi: 10.1089/cdd.1986.3.261. [DOI] [PubMed] [Google Scholar]
  29. Mayes J. T., Thistlethwaite J. R., Jr, Stuart J. K., Buckingham M. R., Stuart F. P. Reexposure to OKT3 in renal allograft recipients. Transplantation. 1988 Feb;45(2):349–353. [PubMed] [Google Scholar]
  30. Nepom G. T., Hellström K. E. Anti-idiotypic antibodies and the induction of specific tumor immunity. Cancer Metastasis Rev. 1987;6(4):489–502. doi: 10.1007/BF00047464. [DOI] [PubMed] [Google Scholar]
  31. Perkins A. C., Pimm M. V., Powell M. C. The implications of patient antibody response for the clinical usefulness of immunoscintigraphy. Nucl Med Commun. 1988 Apr;9(4):273–282. [PubMed] [Google Scholar]
  32. Pimm M. V., Caten J. E., Clegg J. A., Jacobs E., Baldwin R. W. Comparative biodistribution of methotrexate and monoclonal antibody-methotrexate complexes in mice. J Pharm Pharmacol. 1987 Sep;39(9):764–767. doi: 10.1111/j.2042-7158.1987.tb06990.x. [DOI] [PubMed] [Google Scholar]
  33. Pimm M. V., Perkins A. C., Armitage N. C., Baldwin R. W. The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Med. 1985 Sep;26(9):1011–1023. [PubMed] [Google Scholar]
  34. Press O. W., Appelbaum F., Ledbetter J. A., Martin P. J., Zarling J., Kidd P., Thomas E. D. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987 Feb;69(2):584–591. [PubMed] [Google Scholar]
  35. Press O. W., Hansen J. A., Farr A., Martin P. J. Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes. Cancer Res. 1988 Apr 15;48(8):2249–2257. [PubMed] [Google Scholar]
  36. Sandvig K., Olsnes S., Petersen O. W., van Deurs B. Acidification of the cytosol inhibits endocytosis from coated pits. J Cell Biol. 1987 Aug;105(2):679–689. doi: 10.1083/jcb.105.2.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sears H. F., Herlyn D., Steplewski Z., Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 1985 Nov;45(11 Pt 2):5910–5913. [PubMed] [Google Scholar]
  38. Shaw D. R., Khazaeli M. B., Sun L. K., Ghrayeb J., Daddona P. E., McKinney S., LoBuglio A. F. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol. 1987 Jun 15;138(12):4534–4538. [PubMed] [Google Scholar]
  39. Spitler L. E., del Rio M., Khentigan A., Wedel N. I., Brophy N. A., Miller L. L., Harkonen W. S., Rosendorf L. L., Lee H. M., Mischak R. P. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res. 1987 Mar 15;47(6):1717–1723. [PubMed] [Google Scholar]
  40. Tedder T. F., Goldmacher V. S., Lambert J. M., Schlossman S. F. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system. J Immunol. 1986 Aug 15;137(4):1387–1391. [PubMed] [Google Scholar]
  41. Vaughan A. T., Anderson P., Dykes P. W., Chapman C. E., Bradwell A. R. Limitations to the killing of tumours using radiolabelled antibodies. Br J Radiol. 1987 Jun;60(714):567–572. doi: 10.1259/0007-1285-60-714-567. [DOI] [PubMed] [Google Scholar]
  42. Viale G., Grassi F., Pelagi M., Alzani R., Ménard S., Miotti S., Buffa R., Gini A., Siccardi A. G. Anti-human tumor antibodies induced in mice and rabbits by "internal image" anti-idiotypic monoclonal immunoglobulins. J Immunol. 1987 Dec 15;139(12):4250–4255. [PubMed] [Google Scholar]
  43. Vitetta E. S., Fulton R. J., May R. D., Till M., Uhr J. W. Redesigning nature's poisons to create anti-tumor reagents. Science. 1987 Nov 20;238(4830):1098–1104. doi: 10.1126/science.3317828. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES